Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Narjust FlorezAzzouqa Abdel-GhaniSiddhartha YadavKatherine P HoverstenClay T ReedAndrea N SitekElizabeth Ann L EnningaJonas PaludoJesus Vera AguileraKonstantinos LeventakosYanyan LouLisa A KottschadeHaidong DongAaron S MansfieldRami ManochakianAlex A AdjeiRoxana S DroncaPublished in: The oncologist (2019)
The results of this study suggest that women may be at a higher risk for immune-related adverse events (irAEs) compared with men when treated with anti-programmed cell death protein 1 therapy. In addition, women were more likely to develop certain irAEs, including endocrinopathies and pneumonitis. Close follow-up of women undergoing treatment with immune checkpoint inhibitors will allow clinicians to diagnose these treatment-related complications early, potentially reducing their associated morbidity and mortality. In addition, a possible association between irAEs and response to therapy was observed.
Keyphrases
- polycystic ovary syndrome
- pregnancy outcomes
- breast cancer risk
- cervical cancer screening
- pregnant women
- clinical trial
- open label
- type diabetes
- metabolic syndrome
- protein protein
- systemic sclerosis
- bone marrow
- stem cells
- insulin resistance
- small molecule
- interstitial lung disease
- skeletal muscle
- risk factors
- replacement therapy
- smoking cessation
- newly diagnosed